Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.
- DOI
- 10.1186/s13045-026-01830-6
- Published
- 2026-07-20
- Container
- J Hematol Oncol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13045-026-01830-6,
title = {Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.},
author = {Lai MY and Wu HX and He MM and Guan WL and Xu S and Hu H and Xu YL and Wang FH and Xu RH and Qiu MZ.},
year = {2026},
journal = {J Hematol Oncol},
doi = {10.1186/s13045-026-01830-6},
url = {https://doi.org/10.1186/s13045-026-01830-6}
}RIS
TY - JOUR TI - Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. AU - Lai MY AU - Wu HX AU - He MM AU - Guan WL AU - Xu S AU - Hu H AU - Xu YL AU - Wang FH AU - Xu RH AU - Qiu MZ. PY - 2026 JO - J Hematol Oncol DO - 10.1186/s13045-026-01830-6 UR - https://doi.org/10.1186/s13045-026-01830-6 ER -
APA
MY, L., HX, W., MM, H., WL, G., S, X., H, H., YL, X., FH, W., RH, X., & MZ., Q. (2026). Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.. J Hematol Oncol. https://doi.org/10.1186/s13045-026-01830-6
Source records
- europe-pmc · retrieved 2026-09-25T22:52:55.311Z